Opdivo Nivolumab For Sale
Opdivo (nivolumab) is indicated for the treatment of patients with: metastatic melanoma as a single agent or in combination with ipilimumab metastatic non-small cell lung cancer (NSCLC) whose cancer progressed on or after chemotherapy advanced renal cell carcinoma who have received prior anti-angiogenic therapy classical Hodgkin lymphoma that has relapsed or progressed after other treatments recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) .
What is Opdivo (nivolumab) for?
with disease progression on or within 6 months of receiving platinum-based chemotherapy locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
How does Opdivo (nivolumab) work?
Cancer cells can produce proteins (PD-L1 and PD-L2) that attach to this receptor, switching off the T cells. By attaching to the receptor, nivolumab prevents cancer cells from switching off T cells, thereby increasing the ability of the immune system to kill cancer cells
How do I take Opdivo (nivolumab)?
The recommended therapy varies for the different indications and depends on whether nivolumab is used alone or in combination with other therapeutics. Complete information about nivolumab dosage and administration for some of the countries of approval can be found in the official prescribing information listed in our references section